Mechanistic description
The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a proximal molecular phenotype, then a disease-relevant phenotype, in that order.
Mechanism / pathway
- ALS
- neurodegeneration
Evidence for (1)
The proposed priority experiment is concrete: myeloid-specific CCR2 blockade with fast/slow motor-unit stratification and NMJ integrity measurements
Evidence against (1)
Therapeutic tractability is not established by the current source evidence.
Evidence matrix
Supporting
- The proposed priority experiment is concrete: myeloid-specific CCR2 blockade with fast/slow motor-unit stratification and NMJ integrity measurements 10.1038/s41467-025-62351-3
Contradicting
- Therapeutic tractability is not established by the current source evidence. 10.1038/s41467-025-62351-3
Cite this hypothesis
Cite this hypothesis
etl-backfill (2026). Perturbation-first validation should precede therapeutic claims for CCL2-CCR2 A…. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-f9c6fa7676
@misc{scidex_hypothesis_hf9c6fa7,
title = {Perturbation-first validation should precede therapeutic claims for CCL2-CCR2 A…},
author = {etl-backfill},
year = {2026},
howpublished = {SciDEX hypothesis},
url = {https://prism.scidex.ai/hypotheses/h-f9c6fa7676},
note = {SciDEX artifact hypothesis:h-f9c6fa7676}
}